SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. (March 2021)

• Record Type: Journal Article
• Authors: Alexander, James L; Moran, Gordon W; Gaya, Daniel R; Raine, Tim; Hart, Ailsa; Kennedy, Nicholas A; Lindsay, James O; MacDonald, Jonathan; Segal, Jonathan P; Sebastian, Shaji; Selinger, Christian P; Parkes, Miles; Smith, Philip J; Dhar, Anjan; Subramanian, Sreedhar; Arasaradnam, Ramesh; Lamb, Christopher A; Ahmad, Tariq; Lees, Charlie W; Dobson, Liz; Wakeman, Ruth; Iqbal, Tariq H; Arnott, Ian; Powell, Nick; Norton, Christine; Din, Shahida; Glatter, Jackie; Kammermeier, Jochen; Ramdeen, Madhoor; Quraishi, Nabil; Sagar, Peter; Radford, Shellie; Speight, R. Alexander; Steed, Helen; Mcfarlane, Michael; Hawthorne, A. Barney;
• Is Part Of: Lancet gastroenterology and hepatology. Volume 6:Number 3(2021)
• Page Start: 218
• Page End: 224
• Publication Date: 2021-03
• DOI: 10.1016/S2468-1253(21)00024-8
• Languages: English
• ISSNs: 2468-1253

Abstract

Summary: SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.